A-A-0051631 (DM)
15 August 1986
INTERIM COMMERCIAL ITEM DESCRIPTION
HYDROMORPHONE HYDROCHLORIDE TABLETS, USP
The General Services Administration has authorized the use of this Interim Commercial Item Description which was developed by DLA, Defense Personnel Support Center, Directorate of Medical Materiel, DPSC-ATT, 2800 South 20th Street, Philadelphia, PA 19101, based upon currently available technical information.
Salient Characteristics:
Shall be Hydromorphone Hydrochloride Tablets, USP.
Shall be in accordance with the requirements of the USP.
For Strength 1, shall contain 2.0 mg of Hydromorphone Hydrochloride per tablet, within the applicable assay limits for tablets.
For Strength 2, shall contain 4.0 mg of Hydromorphone Hydrochloride per tablet, within the applicable assay limits for tablets.
Workmanship. The Tablets shall be free from defects which detract from their appearance or impair their serviceability.
Unit. Package (PG). Shall be supplied as 25 reverse-numbered tablets in commercially blister, strip or card packaging. Four such containers, shall be packaged together to constitute the unit of issue.
Contractor certification. The contractor shall certify that the product offered meets the salient characteristics of this description and conforms to the producers’ own drawings, specifications, standards, and quality assurance practices. The Government reserves the right to require proof of such conformance prior to first delivery and thereafter as may be otherwise provided for under the provisions of the contract.
DISTRIBUTION STATEMENT A. Approved for public release; distribution is unlimited.
For Parts Inquires submit RFQ to Parts Hangar, Inc.
© Copyright 2015 Integrated Publishing, Inc.
A Service Disabled Veteran Owned Small Business